{"id":745636,"date":"2018-11-09T06:45:00","date_gmt":"2018-11-09T06:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/"},"modified":"2025-11-07T01:26:54","modified_gmt":"2025-11-07T06:26:54","slug":"new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/","title":{"rendered":"New Data from Investigational Study of LENVIMA\u00ae (lenvatinib) and KEYTRUDA\u00ae (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer\u2019s 33rd Annual Meeting"},"content":{"rendered":"<p class=\"bwalignc\">       First presentation of LENVIMA and KEYTRUDA combination data in        patients with metastatic non-small cell lung cancer, metastatic melanoma        and metastatic urothelial carcinoma from Study 111\/KEYNOTE-146     <\/p>\n<p class=\"bwalignc\">       New data support ongoing broad clinical program for LENVIMA and        KEYTRUDA combination across multiple tumor types     <\/p>\n<p>TOKYO &amp; KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) and<br \/>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced results from presentations of new data and analyses of<br \/>\n      LENVIMA<sup>\u00ae<\/sup> (lenvatinib), an orally available kinase inhibitor<br \/>\n      discovered by Eisai, in combination with Merck\u2019s anti-PD-1 therapy<br \/>\n      KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) in three different tumor types \u2013<br \/>\n      metastatic non-small cell lung cancer (NSCLC) (Abstract #11147),<br \/>\n      metastatic melanoma (Abstract #11187) and metastatic urothelial<br \/>\n      carcinoma (Abstract #11201).\n    <\/p>\n<p>\n      These data from the Study 111\/KEYNOTE-146 Phase 1b\/2 trial will be<br \/>\n      presented at the 33<sup>rd<\/sup> Annual Meeting of the Society for<br \/>\n      Immunotherapy of Cancer (SITC) in Washington, D.C. from November 9-11.<br \/>\n      In the interim analyses of the studies across three tumor types, the<br \/>\n      LENVIMA and KEYTRUDA combination demonstrated encouraging anti-tumor<br \/>\n      activity. These data support further evaluation of the combination.<br \/>\n      LENVIMA and KEYTRUDA are not approved for use in combination in any<br \/>\n      cancer types today.\n    <\/p>\n<p>\n      \u201cWe are increasingly confident that these interim analyses of new<br \/>\n      clinical trial data on the combination of LENVIMA and KEYTRUDA in<br \/>\n      non-small cell lung cancer, melanoma and urothelial cancer continue to<br \/>\n      verify the potential of this combination,\u201d said Dr. Takashi Owa, Vice<br \/>\n      President and Chief Medicine Creation Officer, Oncology Business Group<br \/>\n      at Eisai. \u201cThrough our collaboration with Merck, we are doing our utmost<br \/>\n      to be able to provide this combination to patients in need of new<br \/>\n      treatment options as soon as possible.\u201d\n    <\/p>\n<p>\n      \u201cThese early promising data being presented support the clinical<br \/>\n      strategy behind our study of KEYTRUDA in combination with LENVIMA across<br \/>\n      a range of different cancers,\u201d said Dr. Jonathan Cheng, Vice President,<br \/>\n      Oncology Clinical Research, Merck Research Laboratories. \u201cWe look<br \/>\n      forward to continuing our broad clinical research effort in<br \/>\n      collaboration with Eisai to evaluate these two therapies in combination,<br \/>\n      with the goal of improving treatment outcomes for people living with<br \/>\n      cancer.\u201d\n    <\/p>\n<p>\n      <b>Trial Design and New Data for Study 111\/KEYNOTE-146<\/b>\n    <\/p>\n<p>\n      Study 111\/KEYNOTE-146 is a multi-center, open-label, single-arm, Phase<br \/>\n      1b\/2 basket trial (ClinicalTrials.gov, NCT02501096) evaluating the<br \/>\n      combination of LENVIMA (20 mg\/day) with KEYTRUDA (200 mg intravenously<br \/>\n      every three weeks) in patients with selected solid tumors (metastatic<br \/>\n      endometrial cancer, metastatic head and neck cancer, metastatic<br \/>\n      melanoma, metastatic NSCLC, metastatic renal cell carcinoma and<br \/>\n      metastatic urothelial carcinoma). Patients were not preselected based on<br \/>\n      PD-L1 tumor expression status. The primary endpoint of the Phase 1b<br \/>\n      study was to determine the maximum tolerated dose of LENVIMA and<br \/>\n      KEYTRUDA in combination. The primary endpoint of the Phase 2 portion is<br \/>\n      investigator-assessed objective response rate (ORR) at week 24 based on<br \/>\n      immune-related RECIST (irRECIST). The secondary efficacy endpoints<br \/>\n      included ORR, progression-free survival (PFS) and duration of response<br \/>\n      (DOR) for patients with complete or partial responses. Data from Study<br \/>\n      111\/KEYNOTE-146 are being presented at SITC\u2019s 33<sup>rd<\/sup> Annual<br \/>\n      Meeting from the metastatic NSCLC, metastatic melanoma and metastatic<br \/>\n      urothelial carcinoma cohorts.\n    <\/p>\n<p>\n      <i><br \/>\n<b>Phase 1b\/2 trial of lenvatinib in combination with pembrolizumab<br \/>\n      in patients with NSCLC (Abstract #11147\/Poster #P392)<\/b><br \/>\n<\/i>\n    <\/p>\n<p>\n      As of data cutoff on March 1, 2018, 21 patients with metastatic NSCLC<br \/>\n      who either had no prior therapy or had received up to two prior lines of<br \/>\n      therapy were enrolled in this Phase 2 cohort. The primary endpoint of<br \/>\n      ORR at week 24 per irRECIST was 33.3% (95% CI: 14.6-57.0). For secondary<br \/>\n      endpoints, median PFS per irRECIST was 5.9 months (95% CI: 2.3-13.8),<br \/>\n      and the PFS rate at 12 months per irRECIST was 29.0% (95% CI:<br \/>\n      10.2-51.0). Median DOR was 10.9 months (95% CI: 2.4-not estimable).<br \/>\n      Grade 3 treatment-related adverse events (TRAEs) occurred in 10 patients<br \/>\n      (48%), and Grade 4 TRAEs occurred in one patient (5%). The most common<br \/>\n      TRAEs (any grade) \u226530% were decreased appetite (67%), fatigue (62%),<br \/>\n      hypothyroidism (43%), diarrhea (43%), proteinuria (43%), arthralgia<br \/>\n      (33%) and hypertension (33%). There was one treatment-related death.\n    <\/p>\n<p>\n      <i><br \/>\n<b>Phase 1b\/2 trial of lenvatinib in combination with pembrolizumab<br \/>\n      in patients with advanced melanoma (Abstract #11187\/Poster #P391)<\/b><br \/>\n<\/i>\n    <\/p>\n<p>\n      As of March 1, 2018, 21 patients with metastatic melanoma who either had<br \/>\n      no prior therapy or had received up to two prior lines of therapy were<br \/>\n      enrolled in this cohort. The primary endpoint of ORR at week 24 per<br \/>\n      irRECIST was 47.6% (95% CI: 25.7-70.2). For secondary endpoints, median<br \/>\n      PFS was 5.5 months (95% CI: 2.6-15.8), and the PFS rate at 12 months was<br \/>\n      34.7% (95% CI: 14.5-56.0). In addition, median DOR was 12.5 months (95%<br \/>\n      CI: 2.7-not estimable). All patients experienced at least one TRAE.<br \/>\n      Grade 3 or 4 TRAEs occurred in 14 patients (67%). The most common TRAEs<br \/>\n      (any grade) \u226530% were fatigue (52%), decreased appetite (48%), diarrhea<br \/>\n      (48%), hypertension (48%), dysphonia (43%), nausea (43%), arthralgia<br \/>\n      (33%) and proteinuria (33%). There were no treatment-related deaths.\n    <\/p>\n<p>\n      <i><br \/>\n<b>Phase 1b\/2 trial of lenvatinib in combination with pembrolizumab<br \/>\n      in patients with urothelial cancer (Abstract #11201\/Poster #P393)<\/b><br \/>\n<\/i>\n    <\/p>\n<p>\n      As of March 1, 2018, 20 patients with metastatic urothelial cancer who<br \/>\n      either had no prior therapy or had received up to two prior lines of<br \/>\n      therapy were enrolled in this cohort. The primary endpoint of ORR at<br \/>\n      week 24 per irRECIST was 25% (95% CI: 9-49). For secondary endpoints,<br \/>\n      median PFS was 5.4 months (95% CI: 1.3-not estimable). Eighteen patients<br \/>\n      (90%) experienced TRAEs. Grade 3 or 4 TRAEs occurred in 10 patients<br \/>\n      (50%). The most common TRAEs (any grade) \u226530% were proteinuria (45%),<br \/>\n      diarrhea (40%), hypertension (35%), fatigue (30%) and hypothyroidism<br \/>\n      (30%). There was one treatment-related death.\n    <\/p>\n<p>\n      <b>About LENVIMA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (lenvatinib) capsules 10 mg<br \/>\n      and 4 mg<\/b>\n    <\/p>\n<p>\n      LENVIMA<sup>\u00ae<\/sup>&nbsp;(lenvatinib) is a kinase inhibitor that is indicated<br \/>\n      in the U.S.:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        For the treatment of patients with locally recurrent or metastatic,<br \/>\n        progressive radioactive iodine-refractory differentiated thyroid<br \/>\n        cancer (DTC)\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In combination with everolimus, for the treatment of patients with<br \/>\n        advanced renal cell carcinoma (RCC) following one prior<br \/>\n        anti-angiogenic therapy\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        For the first-line treatment of patients with unresectable<br \/>\n        hepatocellular carcinoma (HCC)\n      <\/li>\n<\/ul>\n<p>\n      LENVIMA, discovered and developed by Eisai, is a kinase inhibitor that<br \/>\n      inhibits the kinase activities of vascular endothelial growth factor<br \/>\n      (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA<br \/>\n      inhibits other kinases that have been implicated in pathogenic<br \/>\n      angiogenesis, tumor growth, and cancer progression in addition to their<br \/>\n      normal cellular functions, including fibroblast growth factor (FGF)<br \/>\n      receptors FGFR1-4; the platelet derived growth factor receptor alpha<br \/>\n      (PDGFR\u03b1), KIT, and RET. The combination of lenvatinib and everolimus<br \/>\n      showed increased anti-angiogenic and anti-tumor activity as demonstrated<br \/>\n      by decreased human endothelial cell proliferation, tube formation, and<br \/>\n      VEGF signaling <i>in vitro<\/i> and tumor volume in mouse xenograft<br \/>\n      models of human renal cell cancer greater than each drug alone.<br \/>\n      Lenvatinib also exhibited antiproliferative activity in hepatocellular<br \/>\n      carcinoma cell lines dependent on activated FGFR signaling with a<br \/>\n      concurrent inhibition of FGF-receptor substrate 2\u03b1 (FRS2\u03b1)<br \/>\n      phosphorylation.\n    <\/p>\n<p>\n      <b>Important Safety Information<\/b>\n    <\/p>\n<p>\n      <b>Warnings and Precautions<\/b>\n    <\/p>\n<p>\n      <b>Hypertension.<\/b> In DTC, hypertension occurred in 73% of patients on<br \/>\n      LENVIMA (44% grade 3-4). In RCC, hypertension occurred in 42% of<br \/>\n      patients on LENVIMA + everolimus (13% grade 3). Systolic blood pressure<br \/>\n      \u2265160 mmHg occurred in 29% of patients, and 21% had diastolic blood<br \/>\n      pressure \u2265100 mmHg. In HCC, hypertension occurred in 45% of<br \/>\n      LENVIMA-treated patients (24% grade 3). Grade 4 hypertension was not<br \/>\n      reported in HCC.\n    <\/p>\n<p>\n      Serious complications of poorly controlled hypertension have been<br \/>\n      reported. Control blood pressure prior to initiation. Monitor blood<br \/>\n      pressure after 1 week, then every 2 weeks for the first 2 months, and<br \/>\n      then at least monthly thereafter during treatment. Withhold and resume<br \/>\n      at reduced dose when hypertension is controlled or permanently<br \/>\n      discontinue based on severity.\n    <\/p>\n<p>\n      <b>Cardiac Dysfunction.<\/b> Serious and fatal cardiac dysfunction can<br \/>\n      occur with LENVIMA. Across clinical trials in 799 patients with DTC,<br \/>\n      RCC, and HCC, grade 3 or higher cardiac dysfunction occurred in 3% of<br \/>\n      LENVIMA-treated patients. Monitor for clinical symptoms or signs of<br \/>\n      cardiac dysfunction. Withhold and resume at reduced dose upon recovery<br \/>\n      or permanently discontinue based on severity.\n    <\/p>\n<p>\n      <b>Arterial Thromboembolic Events.<\/b> Among patients receiving LENVIMA<br \/>\n      or LENVIMA + everolimus, arterial thromboembolic events of any severity<br \/>\n      occurred in 2% of patients in RCC and HCC and 5% in DTC. Grade 3-5<br \/>\n      arterial thromboembolic events ranged from 2% to 3% across all clinical<br \/>\n      trials.\n    <\/p>\n<p>\n      Permanently discontinue following an arterial thrombotic event. The<br \/>\n      safety of resuming after an arterial thromboembolic event has not been<br \/>\n      established and LENVIMA has not been studied in patients who have had an<br \/>\n      arterial thromboembolic event within the previous 6 months.\n    <\/p>\n<p>\n      <b>Hepatotoxicity.<\/b> Across clinical studies enrolling 1,327<br \/>\n      LENVIMA-treated patients with malignancies other than HCC, serious<br \/>\n      hepatic adverse reactions occurred in 1.4% of patients. Fatal events,<br \/>\n      including hepatic failure, acute hepatitis and hepatorenal syndrome,<br \/>\n      occurred in 0.5% of patients. In HCC, hepatic encephalopathy occurred in<br \/>\n      8% of LENVIMA-treated patients (5% grade 3-5). Grade 3-5 hepatic failure<br \/>\n      occurred in 3% of LENVIMA-treated patients. 2% of patients discontinued<br \/>\n      LENVIMA due to hepatic encephalopathy and 1% discontinued due to hepatic<br \/>\n      failure.\n    <\/p>\n<p>\n      Monitor liver function prior to initiation, then every 2 weeks for the<br \/>\n      first 2 months, and at least monthly thereafter during treatment.<br \/>\n      Monitor patients with HCC closely for signs of hepatic failure,<br \/>\n      including hepatic encephalopathy. Withhold and resume at reduced dose<br \/>\n      upon recovery or permanently discontinue based on severity.\n    <\/p>\n<p>\n      <b>Renal Failure or Impairment.<\/b> Serious including fatal renal<br \/>\n      failure or impairment can occur with LENVIMA. Renal impairment was<br \/>\n      reported in 14% and 7% of LENVIMA-treated patients in DTC and HCC,<br \/>\n      respectively. Grade 3-5 renal failure or impairment occurred in 3% of<br \/>\n      patients with DTC and 2% of patients with HCC, including 1 fatal event<br \/>\n      in each study. In RCC, renal impairment or renal failure was reported in<br \/>\n      18% of LENVIMA + everolimus\u2013treated patients (10% grade 3).\n    <\/p>\n<p>\n      Initiate prompt management of diarrhea or dehydration\/hypovolemia.<br \/>\n      Withhold and resume at reduced dose upon recovery or permanently<br \/>\n      discontinue for renal failure or impairment based on severity.\n    <\/p>\n<p>\n      <b>Proteinuria.<\/b> In DTC and HCC, proteinuria was reported in 34% and<br \/>\n      26% of LENVIMA-treated patients, respectively. Grade 3 proteinuria<br \/>\n      occurred in 11% and 6% in DTC and HCC, respectively. In RCC, proteinuria<br \/>\n      occurred in 31% of patients receiving LENVIMA + everolimus (8% grade 3).\n    <\/p>\n<p>\n      Monitor for proteinuria prior to initiation and periodically during<br \/>\n      treatment. If urine dipstick proteinuria \u22652+ is detected, obtain a<br \/>\n      24-hour urine protein. Withhold and resume at reduced dose upon recovery<br \/>\n      or permanently discontinue based on severity.\n    <\/p>\n<p>\n      <b>Diarrhea.<\/b> Of the 737 LENVIMA-treated patients in DTC and HCC,<br \/>\n      diarrhea occurred in 49% (6% grade 3). In RCC, diarrhea occurred in 81%<br \/>\n      of LENVIMA + everolimus\u2013treated patients (19% grade 3). Diarrhea was the<br \/>\n      most frequent cause of dose interruption\/reduction, and diarrhea<br \/>\n      recurred despite dose reduction.\n    <\/p>\n<p>\n      Promptly initiate management of diarrhea. Withhold and resume at reduced<br \/>\n      dose upon recovery or permanently discontinue based on severity.\n    <\/p>\n<p>\n      <b>Fistula Formation and Gastrointestinal Perforation.<\/b> Of the 799<br \/>\n      patients treated with LENVIMA or LENVIMA + everolimus in DTC, RCC, and<br \/>\n      HCC, fistula or gastrointestinal perforation occurred in 2%. Fistulas<br \/>\n      and gastrointestinal perforations have also been reported in other<br \/>\n      lenvatinib clinical trials and in post-marketing experience.<br \/>\n      Pneumothorax has been reported with and without clear evidence of a<br \/>\n      bronchopleural fistula. Some reports of gastrointestinal perforation,<br \/>\n      fistula, and pneumothorax occurred in association with tumor regression<br \/>\n      or necrosis. In most cases of fistula formation or gastrointestinal<br \/>\n      perforation, risk factors such as prior surgery or radiotherapy were<br \/>\n      present.\n    <\/p>\n<p>\n      Permanently discontinue in patients who develop gastrointestinal<br \/>\n      perforation of any severity or grade 3-4 fistula.\n    <\/p>\n<p>\n      <b>QT Interval Prolongation.<\/b> In DTC, QT\/QTc interval prolongation<br \/>\n      occurred in 9% of LENVIMA-treated patients and QT interval prolongation<br \/>\n      of &gt;500 ms occurred in 2%. In RCC, QTc interval increases of &gt;60 ms<br \/>\n      occurred in 11% of patients receiving LENVIMA + everolimus and QTc<br \/>\n      interval &gt;500 ms occurred in 6%. In HCC, QTc interval increases of &gt;60<br \/>\n      ms occurred in 8% of LENVIMA-treated patients and QTc interval &gt;500 ms<br \/>\n      occurred in 2%.\n    <\/p>\n<p>\n      Monitor and correct electrolyte abnormalities at baseline and<br \/>\n      periodically during treatment. Monitor electrocardiograms in patients<br \/>\n      with congenital long QT syndrome, congestive heart failure,<br \/>\n      bradyarrhythmias, or those who are taking drugs known to prolong the QT<br \/>\n      interval, including Class Ia and III antiarrhythmics. Withhold and<br \/>\n      resume at reduced dose upon recovery based on severity.\n    <\/p>\n<p>\n      <b>Hypocalcemia.<\/b> In DTC, grade 3-4 hypocalcemia occurred in 9% of<br \/>\n      LENVIMA-treated patients. In 65% of cases, hypocalcemia improved or<br \/>\n      resolved following calcium supplementation with or without dose<br \/>\n      interruption or dose reduction. In RCC, grade 3-4 hypocalcemia occurred<br \/>\n      in 6% of LENVIMA + everolimus\u2013treated patients. In HCC, grade 3<br \/>\n      hypocalcemia occurred in 0.8% of LENVIMA-treated patients.\n    <\/p>\n<p>\n      Monitor blood calcium levels at least monthly and replace calcium as<br \/>\n      necessary during treatment. Withhold and resume at reduced dose upon<br \/>\n      recovery or permanently discontinue depending on severity.\n    <\/p>\n<p>\n      <b>Reversible Posterior Leukoencephalopathy Syndrome.<\/b> Across<br \/>\n      clinical studies of 1,823 patients who received LENVIMA as a single<br \/>\n      agent, RPLS occurred in 0.3%. Confirm diagnosis of RPLS with MRI.<br \/>\n      Withhold and resume at reduced dose upon recovery or permanently<br \/>\n      discontinue depending on severity and persistence of neurologic symptoms.\n    <\/p>\n<p>\n      <b>Hemorrhagic Events.<\/b> Serious including fatal hemorrhagic events<br \/>\n      can occur with LENVIMA. In DTC, RCC, and HCC clinical trials,<br \/>\n      hemorrhagic events, of any grade, occurred in 29% of the 799 patients<br \/>\n      treated with LENVIMA as a single agent or in combination with<br \/>\n      everolimus. The most frequently reported hemorrhagic events (all grades<br \/>\n      and occurring in at least 5% of patients) were epistaxis and hematuria.<br \/>\n      In DTC, grade 3-5 hemorrhage occurred in 2% of LENVIMA-treated patients,<br \/>\n      including 1 fatal intracranial hemorrhage among 16 patients who received<br \/>\n      LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage<br \/>\n      occurred in 8% of LENVIMA + everolimus\u2013treated patients, including 1<br \/>\n      fatal cerebral hemorrhage. In HCC, grade 3-5 hemorrhage occurred in 5%<br \/>\n      of LENVIMA-treated patients, including 7 fatal hemorrhagic events.\n    <\/p>\n<p>\n      Serious tumor-related bleeds, including fatal hemorrhagic events,<br \/>\n      occurred in LENVIMA-treated patients in clinical trials and in the<br \/>\n      postmarketing setting. In postmarketing surveillance, serious and fatal<br \/>\n      carotid artery hemorrhages were seen more frequently in patients with<br \/>\n      anaplastic thyroid carcinoma (ATC) than other tumors. Safety and<br \/>\n      effectiveness of LENVIMA in patients with ATC have not been demonstrated<br \/>\n      in clinical trials.\n    <\/p>\n<p>\n      Consider the risk of severe or fatal hemorrhage associated with tumor<br \/>\n      invasion or infiltration of major blood vessels (eg, carotid artery).<br \/>\n      Withhold and resume at reduced dose upon recovery or permanently<br \/>\n      discontinue based on severity.\n    <\/p>\n<p>\n      <b>Impairment of Thyroid Stimulating Hormone Suppression\/Thyroid<br \/>\n      Dysfunction.<\/b> LENVIMA impairs exogenous thyroid suppression. In DTC,<br \/>\n      88% of patients had baseline thyroid stimulating hormone (TSH) level<br \/>\n      \u22640.5 mU\/L. In patients with normal TSH at baseline, elevation of TSH<br \/>\n      level &gt;0.5 mU\/L was observed post baseline in 57% of LENVIMA-treated<br \/>\n      patients. In RCC and HCC, grade 1 or 2 hypothyroidism occurred in 24% of<br \/>\n      LENVIMA + everolimus\u2013treated patients and 21% of LENVIMA-treated<br \/>\n      patients, respectively. In patients with normal or low TSH at baseline,<br \/>\n      elevation of TSH was observed post baseline in 70% of LENVIMA-treated<br \/>\n      patients in HCC and 60% of LENVIMA + everolimus\u2013treated patients in RCC.\n    <\/p>\n<p>\n      Monitor thyroid function prior to initiation and at least monthly during<br \/>\n      treatment. Treat hypothyroidism according to standard medical practice.\n    <\/p>\n<p>\n      <b>Wound Healing Complications.<\/b> Wound healing complications,<br \/>\n      including fistula formation and wound dehiscence, can occur with<br \/>\n      LENVIMA. Withhold for at least 6 days prior to scheduled surgery. Resume<br \/>\n      after surgery based on clinical judgment of adequate wound healing.<br \/>\n      Permanently discontinue in patients with wound healing complications.\n    <\/p>\n<p>\n      <b>Embryo-fetal Toxicity.<\/b> Based on its mechanism of action and data<br \/>\n      from animal reproduction studies, LENVIMA can cause fetal harm when<br \/>\n      administered to pregnant women. In animal reproduction studies, oral<br \/>\n      administration of lenvatinib during organogenesis at doses below the<br \/>\n      recommended clinical doses resulted in embryotoxicity, fetotoxicity, and<br \/>\n      teratogenicity in rats and rabbits. Advise pregnant women of the<br \/>\n      potential risk to a fetus; and advise females of reproductive potential<br \/>\n      to use effective contraception during treatment with LENVIMA and for at<br \/>\n      least 30 days after the last dose.\n    <\/p>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<p>\n      In DTC, the most common adverse reactions (\u226530%) observed in<br \/>\n      LENVIMA-treated patients were hypertension (73%), fatigue (67%),<br \/>\n      diarrhea (67%), arthralgia\/myalgia (62%), decreased appetite (54%),<br \/>\n      decreased weight (51%), nausea (47%), stomatitis (41%), headache (38%),<br \/>\n      vomiting (36%), proteinuria (34%), palmar-plantar erythrodysesthesia<br \/>\n      syndrome (32%), abdominal pain (31%), and dysphonia (31%). The most<br \/>\n      common serious adverse reactions (\u22652%) were pneumonia (4%), hypertension<br \/>\n      (3%), and dehydration (3%). Adverse reactions led to dose reductions in<br \/>\n      68% of LENVIMA-treated patients; 18% discontinued LENVIMA. The most<br \/>\n      common adverse reactions (\u226510%) resulting in dose reductions were<br \/>\n      hypertension (13%), proteinuria (11%), decreased appetite (10%), and<br \/>\n      diarrhea (10%); the most common adverse reactions (\u22651%) resulting in<br \/>\n      discontinuation of LENVIMA were hypertension (1%) and asthenia (1%).\n    <\/p>\n<p>\n      In RCC, the most common adverse reactions (\u226530%) observed in LENVIMA +<br \/>\n      everolimus\u2013treated patients were diarrhea (81%), fatigue (73%),<br \/>\n      arthralgia\/myalgia (55%), decreased appetite (53%), vomiting (48%),<br \/>\n      nausea (45%), stomatitis (44%), hypertension (42%), peripheral edema<br \/>\n      (42%), cough (37%), abdominal pain (37%), dyspnea (35%), rash (35%),<br \/>\n      decreased weight (34%), hemorrhagic events (32%), and proteinuria (31%).<br \/>\n      The most common serious adverse reactions (\u22655%) were renal failure<br \/>\n      (11%), dehydration (10%), anemia (6%), thrombocytopenia (5%), diarrhea<br \/>\n      (5%), vomiting (5%), and dyspnea (5%). Adverse reactions led to dose<br \/>\n      reductions or interruption in 89% of patients. The most common adverse<br \/>\n      reactions (\u22655%) resulting in dose reductions were diarrhea (21%),<br \/>\n      fatigue (8%), thrombocytopenia (6%), vomiting (6%), nausea (5%), and<br \/>\n      proteinuria (5%). Treatment discontinuation due to an adverse reaction<br \/>\n      occurred in 29% of patients.\n    <\/p>\n<p>\n      In HCC, the most common adverse reactions (\u226520%) observed in<br \/>\n      LENVIMA-treated patients were hypertension (45%), fatigue (44%),<br \/>\n      diarrhea (39%), decreased appetite (34%), arthralgia\/myalgia (31%),<br \/>\n      decreased weight (31%), abdominal pain (30%), palmar-plantar<br \/>\n      erythrodysesthesia syndrome (27%), proteinuria (26%), dysphonia (24%),<br \/>\n      hemorrhagic events (23%), hypothyroidism (21%), and nausea (20%). The<br \/>\n      most common serious adverse reactions (\u22652%) were hepatic encephalopathy<br \/>\n      (5%), hepatic failure (3%), ascites (3%), and decreased appetite (2%).<br \/>\n      Adverse reactions led to dose reductions or interruption in 62% of<br \/>\n      patients. The most common adverse reactions (\u22655%) resulting in dose<br \/>\n      reductions were fatigue (9%), decreased appetite (8%), diarrhea (8%),<br \/>\n      proteinuria (7%), hypertension (6%), and palmar-plantar<br \/>\n      erythrodysesthesia syndrome (5%). Treatment discontinuation due to an<br \/>\n      adverse reaction occurred in 20% of patients. The most common adverse<br \/>\n      reactions (\u22651%) resulting in discontinuation of LENVIMA were fatigue<br \/>\n      (1%), hepatic encephalopathy (2%), hyperbilirubinemia (1%), and hepatic<br \/>\n      failure (1%).\n    <\/p>\n<p>\n      <b>Use in Specific Populations<\/b>\n    <\/p>\n<p>\n      Because of the potential for serious adverse reactions in breastfed<br \/>\n      infants, advise women to discontinue breastfeeding during treatment and<br \/>\n      for at least 1 week after last dose. LENVIMA may impair fertility in<br \/>\n      males and females of reproductive potential.\n    <\/p>\n<p>\n      No dose adjustment is recommended for patients with mild (CLcr 60-89<br \/>\n      mL\/min) or moderate (CLcr 30-59 mL\/min) renal impairment. LENVIMA<br \/>\n      concentrations may increase in patients with DTC or RCC and severe (CLcr<br \/>\n      15-29 mL\/min) renal impairment. Reduce the dose for patients with RCC or<br \/>\n      DTC and severe renal impairment. There is no recommended dose for<br \/>\n      patients with HCC and severe renal impairment. LENVIMA has not been<br \/>\n      studied in patients with end stage renal disease.\n    <\/p>\n<p>\n      No dose adjustment is recommended for patients with HCC and mild hepatic<br \/>\n      impairment (Child-Pugh A). There is no recommended dose for patients<br \/>\n      with HCC with moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic<br \/>\n      impairment.\n    <\/p>\n<p>\n      No dose adjustment is recommended for patients with DTC or RCC and mild<br \/>\n      or moderate hepatic impairment. LENVIMA concentrations may increase in<br \/>\n      patients with DTC or RCC and severe hepatic impairment. Reduce the dose<br \/>\n      for patients with DTC or RCC and severe hepatic impairment.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b>&nbsp;(pembrolizumab) Injection<br \/>\n      100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body&#8217;s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Merck has the industry&#8217;s largest immuno-oncology clinical research<br \/>\n      program. There are currently more than 850 trials studying KEYTRUDA<br \/>\n      across a wide variety of cancers and treatment settings. The KEYTRUDA<br \/>\n      clinical program seeks to understand the role of KEYTRUDA across cancers<br \/>\n      and the factors that may predict a patient&#8217;s likelihood of benefiting<br \/>\n      from treatment with KEYTRUDA, including exploring several different<br \/>\n      biomarkers.\n    <\/p>\n<p>\n      <b>KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Indications and<br \/>\n      Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is<br \/>\n      indicated for the first-line treatment of patients with metastatic<br \/>\n      nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK<br \/>\n      genomic tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with carboplatin and either paclitaxel or<br \/>\n      nab-paclitaxel, is indicated for the first-line treatment of patients<br \/>\n      with metastatic squamous NSCLC.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [Tumor Proportion Score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK<i> <\/i>genomic<br \/>\n      tumor aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the treatment of patients<br \/>\n      with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as determined<br \/>\n      by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for the chemotherapy agents<br \/>\n      administered in combination with KEYTRUDA, as appropriate.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after 3 or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Primary Mediastinal Large B-Cell Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory primary mediastinal large B-cell lymphoma (PMBCL), or<br \/>\n      who have relapsed after 2 or more prior lines of therapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in confirmatory trials. KEYTRUDA is not recommended for<br \/>\n      the treatment of patients with PMBCL who require urgent cytoreductive<br \/>\n      therapy.\n    <\/p>\n<p>\n      In adults with PMBCL, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression. In pediatric<br \/>\n      patients with PMBCL, KEYTRUDA is administered at a dose of 2 mg\/kg (up<br \/>\n      to a maximum of 200 mg) every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who are not eligible<br \/>\n      for cisplatin-containing chemotherapy and whose tumors express PD-L1<br \/>\n      [Combined Positive Score (CPS) \u226510] as determined by an FDA-approved<br \/>\n      test, or in patients who are not eligible for any platinum-containing<br \/>\n      chemotherapy regardless of PD-L1 status. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma (mUC) who have disease<br \/>\n      progression during or following platinum-containing chemotherapy or<br \/>\n      within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      children with MSI-H cancer, KEYTRUDA is administered at a dose of 2<br \/>\n      mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Gastric Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent<br \/>\n      locally advanced or metastatic gastric or gastroesophageal junction<br \/>\n      (GEJ) adenocarcinoma whose tumors express PD-L1 [Combined Positive Score<br \/>\n      (CPS) \u22651] as determined by an FDA-approved test, with disease<br \/>\n      progression on or after two or more prior lines of therapy including<br \/>\n      fluoropyrimidine- and platinum-containing chemotherapy and if<br \/>\n      appropriate, HER2\/neu-targeted therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. The recommended dose of KEYTRUDA is a fixed dose of<br \/>\n      200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      <i>Cervical Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic cervical cancer with disease progression on or after<br \/>\n      chemotherapy whose tumors express PD-L1 (CPS \u22651) as determined by an<br \/>\n      FDA-approved test. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response.<br \/>\n      Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials. The recommended dose of KEYTRUDA is a fixed dose of 200 mg every<br \/>\n      three weeks until disease progression, unacceptable toxicity or up to 24<br \/>\n      months in patients without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      <b>Immune-Mediated Pneumonitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 3.4% (94\/2799) of patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%),<br \/>\n      and occurred more frequently in patients with a history of prior<br \/>\n      thoracic radiation (6.9%) compared to those without (2.9%). Monitor<br \/>\n      patients for signs and symptoms of pneumonitis. Evaluate suspected<br \/>\n      pneumonitis with radiographic imaging. Administer corticosteroids for<br \/>\n      Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2;<br \/>\n      permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Colitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7%<br \/>\n      (48\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%). Monitor patients for signs and symptoms of<br \/>\n      colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Hepatitis<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7%<br \/>\n      (19\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%). Monitor patients for changes in liver function.<br \/>\n      Administer corticosteroids for Grade 2 or greater hepatitis and, based<br \/>\n      on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Immune-Mediated Endocrinopathies<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis, thyroid disorders, and type 1 diabetes<br \/>\n      mellitus. Hypophysitis occurred in 0.6% (17\/2799) of patients, including<br \/>\n      Grade 2 (0.2%), 3 (0.3%), and 4 (&lt;0.1%). Hypothyroidism occurred in 8.5%<br \/>\n      (237\/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The<br \/>\n      incidence of new or worsening hypothyroidism was higher in patients with<br \/>\n      HNSCC, occurring in 15% (28\/192) of patients. Hyperthyroidism occurred<br \/>\n      in 3.4% (96\/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%),<br \/>\n      and thyroiditis occurred in 0.6% (16\/2799) of patients, including Grade<br \/>\n      2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis,<br \/>\n      occurred in 0.2% (6\/2799) of patients.\n    <\/p>\n<p>\n      Monitor patients for signs and symptoms of hypophysitis (including<br \/>\n      hypopituitarism and adrenal insufficiency), thyroid function (prior to<br \/>\n      and periodically during treatment), and hyperglycemia. For hypophysitis,<br \/>\n      administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2 and withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis. Administer hormone replacement for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and<br \/>\n      withhold KEYTRUDA and administer antihyperglycemics in patients with<br \/>\n      severe hyperglycemia.\n    <\/p>\n<p>\n      <b>Immune-Mediated Nephritis and Renal Dysfunction<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3%<br \/>\n      (9\/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Nephritis occurred in 1.7% (7\/405) of<br \/>\n      patients receiving KEYTRUDA in combination with pemetrexed and platinum<br \/>\n      chemotherapy. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      <b>Immune-Mediated Skin Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid, can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA and administer<br \/>\n      corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA<br \/>\n      and refer the patient for specialized care for assessment and treatment.<br \/>\n      If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Other Immune-Mediated Adverse Reactions<\/b>\n    <\/p>\n<p>\n      Immune-mediated adverse reactions, which may be severe or fatal, can<br \/>\n      occur in any organ system or tissue in patients receiving KEYTRUDA and<br \/>\n      may also occur after discontinuation of treatment. For suspected<br \/>\n      immune-mediated adverse reactions, ensure adequate evaluation to confirm<br \/>\n      etiology or exclude other causes. Based on the severity of the adverse<br \/>\n      reaction, withhold KEYTRUDA and administer corticosteroids. Upon<br \/>\n      improvement to Grade 1 or less, initiate corticosteroid taper and<br \/>\n      continue to taper over at least 1 month. Based on limited data from<br \/>\n      clinical studies in patients whose immune-related adverse reactions<br \/>\n      could not be controlled with corticosteroid use, administration of other<br \/>\n      systemic immunosuppressants can be considered. Resume KEYTRUDA when the<br \/>\n      adverse reaction remains at Grade 1 or less following corticosteroid<br \/>\n      taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated<br \/>\n      adverse reaction that recurs and for any life-threatening<br \/>\n      immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and<br \/>\n      encephalitis. In addition, myelitis and myocarditis were reported in<br \/>\n      other clinical trials and postmarketing use.\n    <\/p>\n<p>\n      Treatment with KEYTRUDA may increase the risk of rejection in solid<br \/>\n      organ transplant recipients. Consider the benefit of treatment vs the<br \/>\n      risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      <b>Infusion-Related Reactions<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 0.2% (6\/2799) of patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      <b>Complications of Allogeneic Hematopoietic Stem Cell Transplantation<br \/>\n      (HSCT)<\/b>\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of<br \/>\n      23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6<br \/>\n      developed graft-versus-host disease (GVHD) (1 fatal case) and 2<br \/>\n      developed severe hepatic veno-occlusive disease (VOD) after<br \/>\n      reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute<br \/>\n      GVHD after allogeneic HSCT have also been reported in patients with<br \/>\n      lymphoma who received a PD-1 receptor\u2013blocking antibody before<br \/>\n      transplantation. Follow patients closely for early evidence of<br \/>\n      transplant-related complications such as hyperacute graft-versus-host<br \/>\n      disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile<br \/>\n      syndrome, hepatic veno-occlusive disease (VOD), and other<br \/>\n      immune-mediated adverse reactions.\n    <\/p>\n<p>\n      In patients with a history of allogeneic HSCT, acute GVHD (including<br \/>\n      fatal GVHD) has been reported after treatment with KEYTRUDA. Patients<br \/>\n      who experienced GVHD after their transplant procedure may be at<br \/>\n      increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA<br \/>\n      vs the risk of GVHD in these patients.\n    <\/p>\n<p>\n      <b>Increased Mortality in Patients With Multiple Myeloma<\/b>\n    <\/p>\n<p>\n      In clinical trials in patients with multiple myeloma, the addition of<br \/>\n      KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in<br \/>\n      increased mortality. Treatment of these patients with a PD-1 or PD-L1<br \/>\n      blocking antibody in this combination is not recommended outside of<br \/>\n      controlled clinical trials.\n    <\/p>\n<p>\n      <b>Embryofetal Toxicity<\/b>\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      <b>Adverse Reactions<\/b>\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      permanent discontinuation in more than one patient were colitis (1.4%),<br \/>\n      autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy<br \/>\n      (0.4%), and cardiac failure (0.4%). The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and<br \/>\n      nausea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and<br \/>\n      platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was<br \/>\n      discontinued due to adverse reactions in 20% of 405 patients. The most<br \/>\n      common adverse reactions resulting in permanent discontinuation of<br \/>\n      KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most<br \/>\n      common adverse reactions (\u226520%) with KEYTRUDA were nausea (56%), fatigue<br \/>\n      (56%), constipation (35%), diarrhea (31%), decreased appetite (28%),<br \/>\n      rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia<br \/>\n      (20%).\n    <\/p>\n<p>\n      In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and<br \/>\n      either paclitaxel or nab-paclitaxel in metastatic squamous NSCLC,<br \/>\n      KEYTRUDA was discontinued due to adverse reactions in 15% of 101<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were febrile neutropenia, pneumonia, and urinary<br \/>\n      tract infection. Adverse reactions observed in KEYNOTE-407 were similar<br \/>\n      to those observed in KEYNOTE-189 with the exception that increased<br \/>\n      incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs<br \/>\n      25%) were observed in the KEYTRUDA and chemotherapy arm compared to the<br \/>\n      placebo and chemotherapy arm in KEYNOTE-407.\n    <\/p>\n<p>\n      In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse<br \/>\n      reactions in 8% of 682 patients with metastatic NSCLC. The most common<br \/>\n      adverse event resulting in permanent discontinuation of KEYTRUDA was<br \/>\n      pneumonitis (1.8%). The most common adverse reactions (\u226520%) were<br \/>\n      decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      17% of 192 patients with HNSCC. Serious adverse reactions occurred in<br \/>\n      45% of patients. The most frequent serious adverse reactions reported in<br \/>\n      at least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (\u226520%) were fatigue, decreased appetite, and dyspnea.<br \/>\n      Adverse reactions occurring in patients with HNSCC were generally<br \/>\n      similar to those occurring in patients with melanoma or NSCLC, with the<br \/>\n      exception of increased incidences of facial edema and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5%<br \/>\n      of 210 patients with cHL. Serious adverse reactions occurred in 16% of<br \/>\n      patients; those \u22651% included pneumonia, pneumonitis, pyrexia, dyspnea,<br \/>\n      GVHD, and herpes zoster. Two patients died from causes other than<br \/>\n      disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1<br \/>\n      from septic shock. The most common adverse reactions (\u226520%) were fatigue<br \/>\n      (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea<br \/>\n      (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of<br \/>\n      patients and included arrhythmia (4%), cardiac tamponade (2%),<br \/>\n      myocardial infarction (2%), pericardial effusion (2%), and pericarditis<br \/>\n      (2%). Six (11%) patients died within 30 days of start of treatment. The<br \/>\n      most common adverse reactions (\u226520%) were musculoskeletal pain (30%),<br \/>\n      upper respiratory tract infection and pyrexia (28% each), cough (26%),<br \/>\n      fatigue (23%), and dyspnea (21%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. Serious adverse reactions occurred in 42% of patients; those<br \/>\n      \u22652% were urinary tract infection, hematuria, acute kidney injury,<br \/>\n      pneumonia, and urosepsis. The most common adverse reactions (\u226520%) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%).\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Serious adverse<br \/>\n      reactions occurred in 39% of KEYTRUDA-treated patients; those \u22652% were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis. The most<br \/>\n      common adverse reactions (\u226520%) in patients who received KEYTRUDA were<br \/>\n      fatigue (38%), musculoskeletal pain (32%), pruritus (23%), decreased<br \/>\n      appetite (21%), nausea (21%), and rash (20%).\n    <\/p>\n<p>\n      Adverse reactions occurring in patients with gastric cancer were similar<br \/>\n      to those occurring in patients with melanoma or NSCLC.\n    <\/p>\n<p>\n      In KEYNOTE-158, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 98 patients with recurrent or metastatic cervical cancer. Serious<br \/>\n      adverse reactions occurred in 39% of patients receiving KEYTRUDA; the<br \/>\n      most frequent included anemia (7%), fistula, hemorrhage, and infections<br \/>\n      [except urinary tract infections] (4.1% each). The most common adverse<br \/>\n      reactions (\u226520%) were fatigue (43%), musculoskeletal pain (27%),<br \/>\n      diarrhea (23%), pain and abdominal pain (22% each), and decreased<br \/>\n      appetite (21%).\n    <\/p>\n<p>\n      <b>Lactation<\/b>\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use<\/b>\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a study in 40<br \/>\n      pediatric patients with advanced melanoma, lymphoma, or PD-L1\u2013positive<br \/>\n      advanced, relapsed, or refractory solid tumors, the safety profile was<br \/>\n      similar to that seen in adults treated with KEYTRUDA. Toxicities that<br \/>\n      occurred at a higher rate (\u226515% difference) in these patients when<br \/>\n      compared to adults under 65 years of age were fatigue (45%), vomiting<br \/>\n      (38%), abdominal pain (28%), hypertransaminasemia (28%), and<br \/>\n      hyponatremia (18%).\n    <\/p>\n<p>\n      <b>About the Eisai and Merck Strategic Collaboration<\/b>\n    <\/p>\n<p>\n      In&nbsp;March 2018, Eisai and Merck, known as MSD outside the United States<br \/>\n      and Canada, through an affiliate, entered into a strategic collaboration<br \/>\n      for the worldwide co-development and co-commercialization of LENVIMA.<br \/>\n      Under the agreement, the companies will jointly develop and<br \/>\n      commercialize LENVIMA, both as monotherapy and in combination with<br \/>\n      Merck&#8217;s anti-PD-1 therapy KEYTRUDA. In addition to ongoing clinical<br \/>\n      studies of the combination, the companies will jointly initiate new<br \/>\n      clinical studies evaluating the LENVIMA and KEYTRUDA combination to<br \/>\n      support 11 potential indications in six types of cancer (bladder cancer,<br \/>\n      endometrial cancer, head and neck cancer, hepatocellular carcinoma,<br \/>\n      melanoma and non-small cell lung cancer), as well as a basket trial<br \/>\n      targeting six additional cancer types. The LENVIMA and KEYTRUDA<br \/>\n      combination is not approved in any cancer types today.\n    <\/p>\n<p>\n      <b>About Eisai Inc.<\/b>\n    <\/p>\n<p>\n      At Eisai Inc., <i>human health care <\/i>(<i>hhc<\/i>) is our goal. We<br \/>\n      give our first thoughts to patients and their families, and helping to<br \/>\n      increase the benefits health care provides. As the U.S. pharmaceutical<br \/>\n      subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate<br \/>\n      commitment to patient care that is the driving force behind our efforts<br \/>\n      to discover and develop innovative therapies to help address unmet<br \/>\n      medical needs.\n    <\/p>\n<p>\n      Eisai is a fully integrated pharmaceutical business that operates in two<br \/>\n      global business groups: oncology and neurology (dementia-related<br \/>\n      diseases and neurodegenerative diseases). Each group functions as an<br \/>\n      end-to-end global business with discovery, development, manufacturing<br \/>\n      and marketing capabilities. Our U.S. headquarters, commercial and<br \/>\n      clinical development organizations are located in New Jersey; our<br \/>\n      discovery labs are in Massachusetts and Pennsylvania; and our global<br \/>\n      demand chain organization resides in Maryland and North Carolina. To<br \/>\n      learn more about Eisai Inc., please visit us at <a href=\"https:\/\/us.eisai.com\" rel=\"nofollow\">eisai.com\/us<\/a>.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, the potential<br \/>\n      to bring new hope to people with cancer drives our purpose and<br \/>\n      supporting accessibility to our cancer medicines is our commitment. As<br \/>\n      part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the largest development<br \/>\n      programs in the industry across more than 30 tumor types. We also<br \/>\n      continue to strengthen our portfolio through strategic acquisitions and<br \/>\n      are prioritizing the development of several promising oncology<br \/>\n      candidates with the potential to improve the treatment of advanced<br \/>\n      cancers. For more information about our oncology clinical trials, visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of&nbsp;the United States&nbsp;and&nbsp;Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world&#8217;s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer&#8217;s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc.,&nbsp;Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc.,&nbsp;Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company&#8217;s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in&nbsp;the<br \/>\n      United States&nbsp;and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company&#8217;s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company&#8217;s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company&#8217;s 2017 Annual Report on Form 10-K<br \/>\n      and the company&#8217;s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC&#8217;s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for LENVIMA (lenvatinib) at <\/b><br \/>\n<a href=\"http:\/\/www.lenvima.com\/pdfs\/prescribing-information.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/www.lenvima.com\/pdfs\/prescribing-information.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA at <\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b><br \/>\n      and Medication Guide for KEYTRUDA at <\/b><br \/>\n<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20181109005071r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Eisai Co., Ltd. Media Relations <br \/>+81-(0)3-3817-5120<br \/>or<br \/> Eisai        Inc. Media Relations <br \/>Michele Randazzo, 201-746-2979<br \/>or<br \/> Eisai        Investor Relations <br \/>+81-(0)3-3817-3016<br \/>or<br \/> Merck        Media Relations <br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Kristen        Drake, 908-334-4688<br \/>or<br \/> Merck Investor Relations <br \/>Teri        Loxam, 908-740-1986<br \/>or<br \/>Michael DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA \u00ae (lenvatinib), an orally available kinase inhibitor discovered by Eisai, in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA \u00ae (pembrolizumab) in three different tumor types \u2013 metastatic non-small cell lung cancer (NSCLC) (Abstract #11147), metastatic melanoma (Abstract #11187) and metastatic urothelial carcinoma (Abstract #11201). These data from the Study 111\/KEYNOTE-146 Phase 1b\/2 trial will be presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C. from November 9-11. In the interim analyses of the studies across three tumor types, the LENVIMA and KEYTRUDA combination demonstrated encouraging anti-tumor activity. These data support further evaluation of the combination. LENVIMA and KEYTRUDA are not approved for<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,138,289,56],"class_list":["post-745636","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology-newsroom","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Data from Investigational Study of LENVIMA\u00ae (lenvatinib) and KEYTRUDA\u00ae (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer\u2019s 33rd Annual Meeting - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Data from Investigational Study of LENVIMA\u00ae (lenvatinib) and KEYTRUDA\u00ae (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer\u2019s 33rd Annual Meeting - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA \u00ae (lenvatinib), an orally available kinase inhibitor discovered by Eisai, in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA \u00ae (pembrolizumab) in three different tumor types \u2013 metastatic non-small cell lung cancer (NSCLC) (Abstract #11147), metastatic melanoma (Abstract #11187) and metastatic urothelial carcinoma (Abstract #11201). These data from the Study 111\/KEYNOTE-146 Phase 1b\/2 trial will be presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C. from November 9-11. In the interim analyses of the studies across three tumor types, the LENVIMA and KEYTRUDA combination demonstrated encouraging anti-tumor activity. These data support further evaluation of the combination. LENVIMA and KEYTRUDA are not approved for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"35 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\\\/\",\"name\":\"New Data from Investigational Study of LENVIMA\u00ae (lenvatinib) and KEYTRUDA\u00ae (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer\u2019s 33rd Annual Meeting - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-11-09T06:45:00+00:00\",\"dateModified\":\"2025-11-07T06:26:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Data from Investigational Study of LENVIMA\u00ae (lenvatinib) and KEYTRUDA\u00ae (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer\u2019s 33rd Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Data from Investigational Study of LENVIMA\u00ae (lenvatinib) and KEYTRUDA\u00ae (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer\u2019s 33rd Annual Meeting - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/","og_locale":"en_US","og_type":"article","og_title":"New Data from Investigational Study of LENVIMA\u00ae (lenvatinib) and KEYTRUDA\u00ae (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer\u2019s 33rd Annual Meeting - Merck.com","og_description":"Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA \u00ae (lenvatinib), an orally available kinase inhibitor discovered by Eisai, in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA \u00ae (pembrolizumab) in three different tumor types \u2013 metastatic non-small cell lung cancer (NSCLC) (Abstract #11147), metastatic melanoma (Abstract #11187) and metastatic urothelial carcinoma (Abstract #11201). These data from the Study 111\/KEYNOTE-146 Phase 1b\/2 trial will be presented at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C. from November 9-11. In the interim analyses of the studies across three tumor types, the LENVIMA and KEYTRUDA combination demonstrated encouraging anti-tumor activity. These data support further evaluation of the combination. LENVIMA and KEYTRUDA are not approved for","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:54+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"35 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/","name":"New Data from Investigational Study of LENVIMA\u00ae (lenvatinib) and KEYTRUDA\u00ae (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer\u2019s 33rd Annual Meeting - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-11-09T06:45:00+00:00","dateModified":"2025-11-07T06:26:54+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-investigational-study-of-lenvima-lenvatinib-and-keytruda-pembrolizumab-combination-in-three-different-tumor-types-presented-at-the-society-for-immunotherapy-of-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New Data from Investigational Study of LENVIMA\u00ae (lenvatinib) and KEYTRUDA\u00ae (pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer\u2019s 33rd Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"b7667220-2bd0-47c1-afd4-b35611c95852","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2018\/11\/1\/1569036_merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2018\/11\/1\/Eisai.Logo_.2.jpg","size":"176271","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-Data-from-Investigational-Study-of-LENVIMA-lenvatinib-and-KEYTRUDA-pembrolizumab-Combination-in-Three-Different-Tumor-Types-Prese-X9HET.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745636\/revisions"}],"predecessor-version":[{"id":3674992,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745636\/revisions\/3674992"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745636"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}